Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Ocugen, Inc (OCGN)

NASDAQ
Currency in USD
Disclaimer
1.240
-0.080(-6.06%)
Closed
After Hours
1.2400.000(0.00%)

OCGN Comments

FDA rushing to approve so they can ship to india
why FDA has to approve to ship to India? India already approved this. Everyone thought FDA would approve this on emergency basis last Tuesday. USA has a surplus of 95% efficacy rated vaccines. This one nowhere near it. Speculation keeps the stock price up.
95% efficacy Vaccines does not work on Double mutant and the triple mutant coming after.
maybe you should go and read articles. most articles state that pfizer and moderns will work on those. Not even sure if ones already vaccinated will accept other company vaccines when the time comes to get booster shots. I think e1 who wants to get vaccinated in USA will get it before this vaccine hits the market.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.